“The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Atopic Dermatitis: Phase 2 Proof-of-Concept Study”, J of Skin, vol. 4, no. 6, p. s93, Oct. 2020, doi: 10.25251/skin.4.supp.93.